Literature DB >> 11536318

Recent studies on the roles of antiglycosphingolipids in the pathogenesis of neurological disorders.

T Ariga1, T Miyatake, R K Yu.   

Abstract

Evidence is mounting to suggest a causal role of humoral immunity arising from antiglycosphingolipid (GSL) antibodies in a variety of neurological disorders. These disorders include the demyelinating and axonal forms of Guillain-Barre syndrome, multifocal motor neuropathy, chronic inflammatory demyelinating polyradiculoneuropathy, and IgM paraproteinemia. Many claims have been made regarding other neurological disorders, which should be carefully scrutinized for their validity, based on several criteria proposed in this review. These criteria include 1) characterization of the causative antigens and immunoglobulins, 2) correlation of the pathological lesions and clinical manifestation of the antigens, 3) establishment of animal models using pure GSLs as the antigens, 4) immunopathogenic mechanisms of the neurodenerative process, 5) mechanisms for the malfunctioning of blood-nerve barrier and the ensuing leakage of circulating antibodies into peripheral nerve parenchyma, and 6) the roles of anti-GSL antibodies that may cause humorally mediated nerve dysfunction and injury as well as interference with ion channel function at the node of Ranvier, where carbohydrate epitopes are located. Finally, the origin of the anti-GSL antibodies is discussed in light of the recent circumstantial evidence pointing to a molecular mimicry mechanism with infectious agents. With a better understanding of the immunopathogenic mechanisms, it will then be possible to devise rational and effective diagnostic and therapeutic strategies for the treatment of these neurological disorders. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11536318     DOI: 10.1002/jnr.1162

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  9 in total

Review 1.  Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases.

Authors:  Robert K Yu; Seigo Usuki; Toshio Ariga
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

2.  Neurophysiological and immunohistochemical studies of IgG anti-GM1 monoclonal antibody on neuromuscular transmission: effects in rat neuromuscular junctions.

Authors:  Sayako Hotta; Takumi Nagaoka; Kyoji Taguchi; Yoshihiko Nakatani; Iku Utsnomiya; Yutaka Masuda; Kenji Abe; Nobuhiro Yuki
Journal:  Neurol Sci       Date:  2013-07-03       Impact factor: 3.307

3.  A new approach to ELISA-based anti-glycolipid antibody evaluation of highly adhesive serum samples.

Authors:  Seigo Usuki; Dawn O'Brien; Michael H Rivner; Robert K Yu
Journal:  J Immunol Methods       Date:  2014-05-23       Impact factor: 2.303

4.  Design of a covalently bonded glycosphingolipid microarray.

Authors:  Emma Arigi; Ola Blixt; Karsten Buschard; Henrik Clausen; Steven B Levery
Journal:  Glycoconj J       Date:  2011-11-22       Impact factor: 2.916

Review 5.  The origin of anti-GM1 antibodies in neuropathies: the "binding site drift" hypothesis.

Authors:  Pablo H H Lopez; Ricardo D Lardone; Fernando J Irazoqui; Mariana Maccioni; Gustavo A Nores
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

Review 6.  The role of glycosphingolipid metabolism in the developing brain.

Authors:  Robert K Yu; Yoshihiko Nakatani; Makoto Yanagisawa
Journal:  J Lipid Res       Date:  2008-10-09       Impact factor: 5.922

Review 7.  Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review.

Authors:  Kenichi Kaida; Toshio Ariga; Robert K Yu
Journal:  Glycobiology       Date:  2009-02-24       Impact factor: 4.313

8.  Inhibition of GM3 synthase attenuates neuropathology of Niemann-Pick disease Type C. by affecting sphingolipid metabolism.

Authors:  Hyun Lee; Jong Kil Lee; Yong Chul Bae; Song Hyun Yang; Nozomu Okino; Edward H Schuchman; Tadashi Yamashita; Jae-Sung Bae; Hee Kyung Jin
Journal:  Mol Cells       Date:  2014-02-19       Impact factor: 5.034

Review 9.  Guillain-Barre syndrome during COVID-19 pandemic: an overview of the reports.

Authors:  Kaveh Rahimi
Journal:  Neurol Sci       Date:  2020-09-02       Impact factor: 3.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.